Being diagnosed with cancer is one of the scariest things imaginable. But a cancer diagnosis doesn't have to be a death ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for ...

Researchers have identified C5aR1 as a novel biomarker for metastasis risk and poor prognosis in patients with cutaneous ...

We all have an appendix. Getting it removed in an emergency in America or Britain can involve a whole different set of ...

The phenomenon of cancer overdiagnosis, the diagnosis of a malignant tumour that, without detection, would never lead to ...

CheckMate 274 is a phase III, randomized, double-blind trial of adjuvant nivolumab versus placebo for muscle-invasive urothelial carcinoma (MIUC) at high risk of recurrence after radical resection.

Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot ...

Treatment with retifanlimab plus carboplatin-paclitaxel statistically significantly reduced the risk of progression or death by 37% compared with placebo plus carboplatin-paclitaxel.

In patients with Barrett esophagus, EAC significantly increased all-cause mortality, but rates remained elevated after excluding EAC-related deaths.